Bioactive cell-hydrogel microcapsules for cell-based drug delivery

Journal of Controlled Release

Volumn 135, Issue 3, 2009, Pages 203-210

  Orive, Gorka ^a   De Castro, María ^a   Kong, Hyun Joon ^b   Hernández, Rosa Ma ^a   Ponce, Sara ^a   Mooney, David J ^b   Pedraz, José Luis ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Alginates; Biomimetic capsules; Cell encapsulation; Cell therapy; Drug delivery; RGD

Indexed keywords

ALGINATE BEADS; ALGINATE POLYMERS; ARGININE-GLYCINE-ASPARTIC ACIDS; BIMODAL MOLECULAR WEIGHT DISTRIBUTIONS; BIOMIMETIC CAPSULES; CELL ENCAPSULATION; CELL THERAPY; CELL-BASED; DRUG RELEASE; HYDROGEL SYSTEMS; IMMOBILIZED CELLS; IN-VITRO; IN-VIVO; MECHANICAL STABILIZATIONS; MICROCAPSULES; MICROENVIRONMENT; POLYMER SYSTEMS; RGD; STABLE ENCAPSULATIONS;

ADHESION; ALGINATE; AMINES; AMINO ACIDS; BIOMIMETICS; CALCIUM; CELL ADHESION; CELL CULTURE; CONTROLLED DRUG DELIVERY; DRUG THERAPY; ENCAPSULATION; FUNCTIONAL POLYMERS; HYDROGELS; MECHANICAL STABILITY; MOLECULAR WEIGHT DISTRIBUTION; ORGANIC ACIDS; POLYMERS; SYSTEM STABILITY;

CELLS;

ALGINIC ACID; BIOMIMETIC MATERIAL; ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMIMETICS; CELL ADHESION; CELL HYDROGEL DRUG DELIVERY SYSTEM; COMPRESSION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG STABILITY; FEMALE; HYDROGEL; IMMOBILIZED CELL; IN VIVO STUDY; MICROCAPSULE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OSMOSIS; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE;

ALGINATES; ANIMALS; BIOCOMPATIBLE MATERIALS; BIOMIMETICS; CAPSULES; CELL LINE; DRUG DELIVERY SYSTEMS; GLUCURONIC ACID; HYDROGEL; MICE; MICE, INBRED C3H; MOLECULAR WEIGHT; MYOBLASTS; OLIGOPEPTIDES; TEMPERATURE; TIME FACTORS; TISSUE SCAFFOLDS;

EID: 63649100991     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.01.005     Document Type: Article

References (34)

1. Lim F., and Sun A.M. Microencapsulated islets as bioartificial endocrine pancreas. Science 210 (1980) 908-910
2. Lanza R.P., Hayes J.L., and Chick W.L. Encapsulated cell technology. Nat. Biotechnol. 14 (1996) 1107-1111
3. Orive G., Hernández R.M., Gascón A.R., et al. Cell encapsulation: highlights and promise. Nat. Med. 9 (2003) 104-107
4. Chang T.M.S. Therapeutic applications of polymeric artificial cells. Nat. Rev. Drug Discov. 4 (2005) 221-235
5. Orive G., Hernández R.M., Gascón A.R., Igartua M., and Pedraz J.L. Cell microencapsulation technology for biomedical purposes: novel insights and challenges. Trends Pharm. Sci. 24 (2003) 207-210
6. Townsend-Nicholson A., and Jayasinghe S.N. Cell electrospinning: a unique biotechnique for encapsulating living organisms for generating active biological microthreads/scaffolds. Biomacromolecules 7 (2006) 3364-3369
7. De Vos P., Faas M.M., Strand B., and Calafiore R. Alginate-based microcapsules for immunoisolation of pancreatic islets. Biomaterials 27 (2006) 5603-5617
8. Lörh M., Hoffmeyer A., Kroger J., et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 357 (2001) 1591-1592
9. Orive G., De Castro M., Ponce S., et al. Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules. Mol. Ther. 12 (2005) 283-289
10. Rokstad A.M., Donati I., Borgogna M., et al. Cell-compatible covalently reinforced beads obtained from a chemoenzymatically engineered alginate. Biomaterials 27 (2006) 4726-4737
11. Calafiore R., Basta G., Luca G., et al. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care 29 (2006) 137-138
12. Kong H.J., Smith M.K., and Mooney D.J. Designing alginate hydrogels to maintain viability of immobilized cells. Biomaterials 24 (2003) 4023-4029
13. Alsberg E., Anderson K.W., Albeiruti A., Rowley J.A., and Mooney D.J. Engineering growing tissues. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 12025-12030
14. Augst A.D., Kong J.J., and Mooney D.J. Alginate hydrogels as biomaterials. Macromol. Biosci. 6 (2006) 623-633
15. Rowley J.A., and Mooney D.J. Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials 20 (1999) 45-53
16. Sohmiya M., Kakiba T., and Kato Y. Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. Eur. J. Endocrinol. 139 (1998) 367-370
17. Lansdown A.B., and Payne M.J. An evaluation of the local reaction and biodegradation of calcium sodium alginate (Kaltostat) following subcutaneous implantation in the rat. J. R. Coll. Surg. Edinb. 39 (1994) 284-288
18. Rowley J.A., and Mooney D.J. Alginate type and RGD density control myoblast phenotype. J. Biomed. Mat. Res. 60 (2006) 217-223
19. Robitaille R., Pariseau J.F., Leblond F.A., Lamoureux M., Lepage Y., and Hallé J.P. Studies on small (< 350 microm) alginate-poly-l-lysine microcapsules. III. Biocompatibility of smaller versus standard microcapsules. J. Biomed. Mater. Res. 44 (1999) 116-120
20. Lum Z.P., Krestow M., Tai I.T., Vacek I., and Sun A.M. Xenografts of rat islets into diabetic mice. An evaluation of new smaller capsules. Transplantation 53 (1992) 1180-1183
21. Chicheportiche D., and Reach G. In vitro kinetics of insulin release by microencapsulated rat islets: effect of the size of the microcapsules. Diabetologia 31 (1998) 54-57
22. Grandoso L., Ponce S., Manuel I., et al. Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats. Int. J. Pharm. 343 (2007) 69-78
23. Schneider B.L., Schwenter F., Pralong W.F., and Aebischer P. Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery. Mol. Ther. 7 (2003) 506-514
24. Macdougall I.C., Gray S.J., Elston O., et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J. Am. Soc. Nephrol. 10 (1999) 2392-2395
25. Ponce S., Orive G., Hernández R.M., et al. In vivo evaluation of EPO-secreting cells immobilized in different alginate-PLL microcapsules. J. Control. Rel. 116 (2006) 28-34
26. Murua A., De Castro M., Orive G., Hernandez R.M., and Pedraz J.L. In vitro characterization and in vivo functionality of erythropoietin-secreting cells immobilized in alginate-poly-l-lysine-alginate microcapsules. Biomacromolecules 8 (2007) 3302-3307
27. Robitaille R., Dusseault J., Henley N., Desbiens K., Labrecque N., and Hallé J.P. Inflammatory response to peritoneal implantation of alginate-poly-l-lysine microcapsules. Biomaterials 26 (2005) 4119-4127
28. Olsen N.V. Central nervous system frontiers for the use of erythropoietin. Clin. Infect. Dis. 37 (2003) S323-S330
29. Martijin de Groot M.S., Schuurs T.A., Leuvenink H.G.D., and Van Schilfgaarde M.R.D. Macrophage overgrowth affects neighboring nonovergrown encapsulated islets. J. Surg. Res. 115 (2003) 235-241
30. Orive G., Tam S.K., Pedraz J.L., and Hallé J.P. Biocompatibility of alginate-poly-l-lysine microcapsules for cell therapy. Biomaterials 27 (2006) 3691-3700
31. Brines M., and Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci. 6 (2005) 484-494
32. Ehrenreich H., Degner D., Meller J., et al. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol. Phychiatry 9 (2004) 42-54
33. Ribatti D., Presta M., Vacca A., et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93 (1999) 2627-2636
34. Zwezdaryk K.J., Coffelt S.B., Figueroa Y.G., et al. Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells. Exp. Hematol. 35 (2007) 640-652